PMN310 interim Phase 1b safety and biomarker signals reported
PMN310, a differentiated antibody targeting toxic amyloid beta oligomers, showed strong interim safety and biomarker signals in a Phase 1b Alzheimer's study. Final results are expected in Q1; PMN is funded through 2027.